Munir Pirmohamed
Munir Pirmohamed is an expert in Pharmacy at University of Liverpool (United Kingdom). As of October 2026, ScienceLeadR ranks Munir Pirmohamed in the top 1% of experts worldwide for Erythema, Hypersensitivity and Genetic Services. Munir Pirmohamed has authored 811 publications, the most recent in 2026, and is an investigator in 5 clinical trials. SLR score: 2,922 (community average: 125). How the SLR is computed.
LeadR Profile
Pharmacy
Subspecialties: Public Health - Genetics - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1990 - 2026
Number : 811
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Incidence and prevalence of Takayasu arteritis in England before and after the COVID-19 pandemic: results from RECORDER. PMID 42626720 — epidemiology, incidence, takayasu arteritis, arteritis, covid-19, prevalence, diagnosis, pandemics | Rheumatol Adv Pract | 2026 | 0 |
| Pharmacogenomics of dolutegravir: A scoping review of evidence, gaps and clinical implications. PMID 42521219 — genes, pharmaceutical preparations, multiple chronic conditions, drug-related side effects and adverse reactions, pharmacology, pharmacology, clinical, therapeutics, pharmacokinetics, dolutegravir | Br J Clin Pharmacol | 2026 | 0 |
| MT-RNR1 genotype testing for preventing aminoglycoside-mediated ototoxicity: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). PMID 42524757 — research design, ototoxicity, point-of-care systems, pharmaceutical preparations, hearing, pharmacology, aminoglycosides, genotype, therapeutics, hearing loss, point-of-care testing, pharmacogenomic testing | Br J Clin Pharmacol | 2026 | 0 |
| Sexual Dysfunction Among Males Living with HIV Receiving Dolutegravir-Based Antiretroviral Therapy in Uganda: A Cross-sectional Study. PMID 42440201 — erectile dysfunction, cross-sectional studies, drug-related side effects and adverse reactions, hiv, prevalence, toxicology, therapeutics, dolutegravir | Drug Saf | 2026 | 1 |
| UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). PMID 42389808 — research design, genes, pharmaceutical preparations, neutropenia, neoplasms, sarcoma, enzymes, pharmacology, genotype, therapeutics, irinotecan, pharmacogenomic testing | Br J Clin Pharmacol | 2026 | 2 |
Clinical Studies 5
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 8
LeadR Networks
Main global connection map